|
|
|
The Pancreas and Pancreatic Cancer Part II |
|
|
|
The Gonzalez-Isaacs Cancer Program
The Pancreas and Pancreatic Cancer Part II
Editor's Note:
In our last issue, Vol. 28 No. 3 Nov./Dec., we reintroduced
our readers to the Gonzalez—Isaacs Cancer Program, an important
alternative approach to the treatment of cancer first
reported on in this magazine in January, 2000. At that juncture
they had recently been awarded a substantial National
Cancer Institute (NCI) grant to conduct a large scale, controlled
clinical trial comparing the success of their approach
in treating inoperable advanced pancreatic cancer with a
control group receiving the best conventional chemotherapy
available. This groundbreaking grant was precipitated
by the positive results of a pilot study of Gonzalez-Isaacs
patients suffering from advanced inoperable pancreatic
cancer conducted between 1993 and 1999. Data published
in the peer-reviewed journal Nutrition and Cancer showed an
effect that went beyond anything previously reported in the
medical literature for this deadly disease.
We stated that should this landmark study, the first major
NCI-NIH trial of an alternative cancer therapy, prove as
successful as the results of the pilot study, then this mode
of treatment could become an accepted therapy for pancreatic
cancer. However, the potential benefit to our society
goes far beyond those individuals who are diagnosed with
pancreatic cancer each year. Also, consider the following. It
is estimated there will be 1,300,000 new cancer cases and
between 550,000 and 650,000 deaths from cancer in the
united States this year. If these projections are accurate,
it means between 45 and 50 percent of all individuals who
contract cancer will eventually die from the disease. And if
the estimates do not account for those persons who perish
from conditions related to the cancer or side effects of cancer
drugs, the fatality figures would be substantially higher.
We also reported the following: In 1999 approximately
$13,700,000,000 ($13.7 billion) was spent on chemotherapy
drugs; exclusive of related expenditures for doctors and
nurses fees, hospital services and confronting the devastating
side effects associated with chemotherapy treatment.
We are convinced if just one percent ($137 million) of the
funds expended on chemotherapy drugs were invested in
funding a national program to integrate the Gonzalez-Isaacs
alternative approach to treating cancer into mainstream
medicine it could:
- Drastically change the quality of life of the 1.3 million individuals who contract cancer each year.
- Significantly improve odds against the reoccurrence of cancer for the five to 10 million cancer survivors.
- Either save the lives or prolong the life expectancy and quality of life of the majority of the 600,000 persons who are expected to perish from cancer each year.
- Significantly reduce the cost of doctors, nurses and hospitals associated with chemotherapy treatment, as well as eliminate its side effects in that the Gonzalez Isaacs program is noninvasive and the nutritional, dietary and detoxification protocols are administered by the patient in his or her own home.
In addition, if 30 percent of the potential chemotherapy
patient population opted for the Gonzalez-Isaacs therapy,
an additional $4 billion would be saved, which would provide
funding for aggressive public education and scientific research
programs targeted at cancer awareness and prevention.
Over the past nearly seven years since our first article in
2000 the approximate annual expenditures for chemotherapy
drugs has nearly tripled to $37 billion and 30 percent
would be a $11.1 billion savings. Also projections are that
over the next decade the incidence of individuals contracting
cancer during their lifetime could rise from one out of
three in the 1990s to one out of two in the 2010s.
When we began our series on the Gonzalez-Isaacs program
in 2000 they had treated over 1500 patients suffering
from cancer as well as other degenerative diseases ranging
from multiple sclerosis and lupus to chronic fatigue. At
that point we requested an opportunity to contact a few of
their patients. Dr. Gonzalez's staff supplied us with a list of
25 patients of whom we contacted 13 and interviewed six.
Three of the six were literally given only a few months to
live, according to their primary physician, prior to beginning
the relationship with the Gonzalez-Isaacs program. All of
the individuals we spoke with were at that time healthy with
a positive outlook and credited their newfound longevity to
the program. And, by the way, most of their spouses had
incorporated the Gonzalez-Isaacs program to some degree
into their own wellness programs.
To briefly review, the three basic components of the Gonzalez-
Isaacs treatment are: An individualized diet, individualized
supplement programs and detoxification routines such as
coffee enemas and juice fasts. Protective pancreatic enzymes
are the core of their cancer protocols but are also an integral
part of their treatment programs for non-cancer diseases.
Also the program is primarily administered by the patient
in their own home.
This article reviews case reports of six more patients with
pancreatic cancer. When reading these reports bear in mind
as stated in the prior article that pancreatic cancer is an
insidiously aggressive illness that kills most of its victims
within three to six months, even with aggressive orthodox
chemotherapy.
Finally, we are planning to run a third article concerning the
six-year study of their alternative program in comparison to
conventional chemotherapy when the statistics are available.
For more information, visit the following Website:
www.dr-gonzalez.com .
|
|
